Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
14-day blinatumomab plus CCCG-ALL 2020 chemotherapy in pediatric MRD-positive B-ALL (day 46)
ChiCTR2100053318Phase 2Recruiting
- Sponsor
- Division of Pediatric Blood Diseases Center State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences
- Start
- Nov 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Division of Pediatric Blood Diseases Center State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences. Primary endpoint: Minimal residual disease (MRD). Started Nov 2021; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2100053318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053318.